Zhejiang Starry Pharmaceutical Co (SHSE:603520) Retained Earnings: ¥258 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603520 Zhejiang Starry Pharmaceutical Co Ltd SHSE:603520
76 GF Score
Price ¥8.61
GF Value ¥10.46
Valuation Modestly Undervalued
! 10 Warning Signs
View Full Analysis

What is Zhejiang Starry Pharmaceutical Co Retained Earnings?

Zhejiang Starry Pharmaceutical Co SHSE:603520 +2.50% 76 Retained Earnings is ¥258 Mil as of Jun. 2026. GuruFocus rates SHSE:603520 with a GF Score™ of 76/100 and a GF Value™ of ¥10.46 (Modestly Undervalued). The stock has 10 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Zhejiang Starry Pharmaceutical Co's retained earnings for the quarter that ended in Jun. 2026 was ¥258 Mil.

Zhejiang Starry Pharmaceutical Co's quarterly retained earnings increased from Dec. 2025 (¥327 Mil) to Mar. 2026 (¥348 Mil) but then declined from Mar. 2026 (¥348 Mil) to Jun. 2026 (¥258 Mil).

Zhejiang Starry Pharmaceutical Co's annual retained earnings declined from Dec. 2023 (¥458 Mil) to Dec. 2024 (¥387 Mil) and declined from Dec. 2024 (¥387 Mil) to Dec. 2025 (¥327 Mil).


Zhejiang Starry Pharmaceutical Co  (SHSE:603520) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Zhejiang Starry Pharmaceutical Co Retained Earnings Historical Data

* Premium members only.

The historical data trend for Zhejiang Starry Pharmaceutical Co's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang Starry Pharmaceutical Co Retained Earnings Chart

Zhejiang Starry Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 689.52 483.95 458.12 387.10 327.26

Zhejiang Starry Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 372.40 350.16 327.26 348.21 257.58
SHSE:603520
76GF Score
Zhejiang Starry Pharmaceutical Co Ltd SHSE:603520
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zhejiang Starry Pharmaceutical Co Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of ¥258 Mil mean?
Zhejiang Starry Pharmaceutical Co (SHSE:603520) has a Retained Earnings of ¥258 Mil as of Jun. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Zhejiang Starry Pharmaceutical Co and its competitors.
Is Zhejiang Starry Pharmaceutical Co's Retained Earnings too high?
Zhejiang Starry Pharmaceutical Co's current Retained Earnings is ¥258 Mil. Overall, Zhejiang Starry Pharmaceutical Co has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Starry Pharmaceutical Co's Retained Earnings compare to ZTS?
Zhejiang Starry Pharmaceutical Co's Retained Earnings of ¥258 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Drug Manufacturers company?
A good Retained Earnings depends on the Drug Manufacturers industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Zhejiang Starry Pharmaceutical Co and its competitors. Zhejiang Starry Pharmaceutical Co's current Retained Earnings is ¥258 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Starry Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Starry Pharmaceutical Co (SHSE:603520) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥10.46, compared to a current price of ¥8.61 — trading 17.7% below its estimated fair value. The current Retained Earnings is ¥258 Mil. Zhejiang Starry Pharmaceutical Co's overall GF Score™ is 76/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Zhejiang Starry Pharmaceutical Co (SHSE:603520), the current Retained Earnings is ¥258 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhejiang Starry Pharmaceutical Co (SHSE:603520) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang Starry Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥8.61 is trading 17.7% below its estimated GF Value™ of ¥10.46. GuruFocus considers Zhejiang Starry Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SHSE:603520:

  • Retained Earnings: ¥258 Mil
  • GF Value™: ¥10.46 vs. price of ¥8.61 (17.7% below fair value)
  • GF Score™: 76/100 with 10 warning signs

No single metric tells the full story. See the SHSE:603520 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zhejiang Starry Pharmaceutical Co Business Description

Address No.1 Sitali Avenue, Modern Industrial Gathering District, Zhejiang Province, Xianju County, Taizhou City, CHN, 317306
Zhejiang Starry Pharmaceutical Co Ltd is engaged in R&D, manufacture and marketing of active ingredient and intermediate X-CT non-ionic contrast agent series and Fluoroquinolones series.
76GF Score

Get the complete analysis for SHSE:603520

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥8.61
Price
¥10.46
GF Value